Core Viewpoint - The company, Hefei Taihe Intelligent Technology Group Co., Ltd., has successfully completed its initial public offering (IPO) and subsequent private placement of shares, with ongoing supervision by designated securities firms to ensure compliance with regulatory requirements [1][3]. Group 1: Initial Public Offering - The company issued 18.99 million shares at a price of RMB 21.91 per share, raising a total of RMB 416.07 million, with a net amount of RMB 41.61 million after deducting issuance costs [1]. - The continuous supervision of the IPO process was initially handled by Dongfang Citic Securities, which will now be succeeded by Haitong Securities due to the company's new private placement [2]. Group 2: Private Placement - The company has received approval for a private placement, raising a total of RMB 350.58 million, with a net amount of RMB 344.49 million after deducting issuance costs [3]. - The private placement shares were listed on the Shanghai Stock Exchange on March 15, 2023, with Haitong Securities acting as the continuous supervising sponsor [3]. Group 3: Continuous Supervision and Compliance - Haitong Securities will oversee the company from March 15, 2023, to December 31, 2024, ensuring compliance with relevant regulations and guidelines [3]. - The company has established a governance structure that meets the requirements for listed companies, with effective execution of its articles of association and meeting procedures [5]. - The company has a complete information disclosure system, fulfilling necessary disclosure obligations without any false statements or omissions [6]. Group 4: Financial and Operational Stability - The company has maintained stable operational conditions, with no significant changes in its business model or market environment [7]. - The company has established a management system for the use of raised funds, ensuring compliance with decision-making procedures and information disclosure [6][7].

Group 1 - Bid Pharma's stock closed at 47.98 yuan, with a decline of 11.15%, resulting in a total market capitalization of 4.361 billion yuan, currently in a state of breaking issue [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 11, 2022, with an issuance of 16.2291 million shares at a price of 88.00 yuan per share [1] - The total amount raised from the issuance was 1.428 billion yuan, with a net amount of 1.309 billion yuan after deducting issuance costs, exceeding the original plan by 874.6428 million yuan [1] Group 2 - The strategic placement of Bid Pharma's issuance involved participation from the underwriting institution's subsidiaries and a special asset management plan for senior management and core employees [2] - The underwriting institution, Haitong Securities, participated in the strategic placement, acquiring 4.00% of the public offering, amounting to 649,164 shares valued at approximately 57.13 million yuan [2] - The annual profit distribution announced on May 19, 2023, indicated a cash dividend of 1.54 yuan per share and a capital reserve increase of 0.4 shares per share, resulting in a total distribution of approximately 99.97 million yuan and an increase of 25.97 million shares [2]

Group 1 - Morgan Fund Management (China) Co., Ltd. has signed fund sales agency agreements with multiple institutions including Guotai Junan Securities, Haitong Securities, E-Hua Buy Fund Sales, and Lead Fund Sales to distribute the Morgan Dual Bond Enhanced Income Bond Fund Class D (Fund Code: 023813) [1] - Investors can conduct subscription, redemption, and regular investment through the aforementioned agencies, with specific procedures and timings determined by the agencies [1] - The announcement includes contact details for each agency for further inquiries [1] Group 2 - Morgan Fund Management (China) Co., Ltd. has added Hengtai Securities as a sales agency for the Morgan Dual Bond Enhanced Income Bond Fund (Class A Code: 000377; Class C Code: 000378; Class D Code: 023813) [3] - Investors can also perform subscription, redemption, and regular investment through Hengtai Securities, with specific procedures governed by Hengtai Securities [3][4] Group 3 - Starting from March 31, 2025, Morgan Fund Management (China) Co., Ltd. will lower the management and custody fees for certain funds and amend related legal documents [5] - The adjustments are made in accordance with relevant laws and fund contracts, and the changes will not adversely affect the interests of fund shareholders [5][6] - Updated fund contracts, custody agreements, and prospectuses will be published on the company's website and the China Securities Regulatory Commission's fund disclosure website [6]

Core Viewpoint - The report highlights a significant decline in revenue and net profit for Huahong Semiconductor, attributed to weak demand in automotive, industrial, and new energy sectors, as well as intense market competition affecting sales prices [2][9]. Financial Performance - Revenue for 2024 is reported at 1,438,830.77 million RMB, a decrease of 11.36% compared to the previous year [17]. - Net profit attributable to shareholders decreased by 80.34%, while net profit excluding non-recurring gains and losses fell by 84.80% [2][17]. - Basic earnings per share dropped by 83.21% to 0.22 RMB, and diluted earnings per share decreased by 83.08% to 0.22 RMB [17][18]. - Total assets increased by 15.36% to 8,793,523.15 million RMB [17]. Operational Overview - The company is under continuous supervision by Guotai Junan Securities and Haitong Securities, with a focus on compliance with relevant regulations and effective governance [4][7]. - No major violations or issues requiring rectification were reported during the supervision period [9][17]. Market and Industry Risks - The semiconductor industry faces cyclical demand fluctuations, with potential risks from economic slowdowns and increased competition [10][12]. - The company must continuously innovate and upgrade its technology to maintain competitiveness in a rapidly evolving market [10][12]. - Risks related to supply chain disruptions, particularly from geopolitical tensions affecting key suppliers, could impact production and operational stability [11][14]. Research and Development - The company has focused on enhancing its core competencies in specialized process technologies, with a total of 4,644 patents granted as of December 2024 [18][19]. - R&D efforts are concentrated on differentiated technologies, including embedded non-volatile memory and power devices, to meet market demands [19][20]. Fund Utilization - As of December 31, 2024, the company reported a balance of 696,643.96 million RMB in its fundraising account, with all funds utilized in compliance with regulatory requirements [21][22].

Core Viewpoint - The report outlines the fundraising and usage status of Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. for the year 2024, confirming compliance with regulatory requirements and detailing the management of raised funds [1][6][7]. Fundraising Overview - The company raised a total of RMB 1,074 million through the issuance of 12 million shares at RMB 8.95 per share, with net proceeds amounting to RMB 974.32 million after deducting issuance costs of RMB 99.68 million [1][3]. - As of December 31, 2024, the total amount used from the raised funds was RMB 486.36 million, with an additional RMB 346.45 million from over-raised funds permanently supplementing working capital [1][3]. Fund Usage and Management - The company utilized RMB 15.24 million of the raised funds during the reporting period and had a remaining balance of RMB 193.10 million in the dedicated account as of December 31, 2024 [1][3]. - A three-party supervision agreement was signed with banks to ensure proper management of the raised funds, and the company has adhered to its internal management procedures [1][4]. Cash Management - The company approved the use of up to RMB 250 million of temporarily idle raised funds for cash management, focusing on safe and liquid investment products [4][8]. - The company engaged in structured deposits and achieved returns from these investments, with no remaining balance in investment products as of the end of the reporting period [5][8]. Compliance and Audit - The report confirms that the company has complied with all relevant regulations regarding the management and usage of raised funds, with no violations reported [6][7]. - The auditing firm PwC provided a verification report affirming that the fundraising and usage report accurately reflects the company's financial activities [6][7].

Group 1 - The stock price of Suochen Technology (688507.SH) fell by 5.76% to 82.92 yuan as of the market close on March 27, 2023, indicating that the stock is currently in a state of decline since its IPO [1] - Suochen Technology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on April 18, 2023, with an issuance of 10,333,400 shares at a price of 245.56 yuan per share, resulting in a total fundraising amount of 253,746.97 million yuan [1] - The net fundraising amount was 231,574.91 million yuan, exceeding the original plan by 134,684.55 million yuan, with the funds allocated for various projects including R&D center construction and marketing network development [1] Group 2 - The company announced a profit distribution plan on June 13, 2023, distributing a cash dividend of 0.15 yuan per share and a capital reserve increase of 0.48 shares for every share held, resulting in a total cash dividend of 6,200,010 yuan and an increase of 19,840,032 shares [2] - The total share capital after the distribution will be 61,173,432 shares, with the ex-dividend date set for June 20, 2023 [2] - For the 2023 annual profit distribution, the company plans to distribute a cash dividend of 3.80 yuan for every 10 shares and a capital reserve increase of 4.60 shares for every 10 shares, with the ex-dividend date set for June 19, 2024 [2]

Group 1 - The stock price of Pava Co., Ltd. (688184.SH) fell by 3.72% to 12.93 yuan, with a total market value of 2.056 billion yuan, currently in a state of breaking issue [1] - Pava Co., Ltd. was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 19, 2022, with an initial public offering of 33,594,557 shares at a price of 51.88 yuan per share [1] - The company raised a total of approximately 1.743 billion yuan from its initial public offering, with a net amount of approximately 1.595 billion yuan after deducting issuance costs [1] Group 2 - The underwriting institution, Haitong Securities, arranged for its subsidiary Haitong Innovation Securities to participate in the strategic placement of 3.44% of the public offering, amounting to approximately 60 million yuan [2] - On July 12, 2023, Pava Co., Ltd. announced a dividend plan of 3.3 yuan per 10 shares and a bonus issue of 2 shares, with the ex-dividend date set for July 19, 2023 [2] - The company's performance report indicated a projected operating revenue of approximately 1.037 billion yuan for 2024, a year-on-year decrease of 11.48%, and a net profit attributable to the parent company of approximately -109.71 million yuan, compared to -9.74 million yuan in the previous year [2]

《关于 A 股部分募集资金投资项目终止并调整投资计划的议案》尚需提交 公司股东会审议。现将有关情况公告如下： 一、A 股首次公开发行股票募集资金的基本情况 经中国证券监督管理委员会《关于同意中集车辆（集团）股份有限公司首次 公开发行股票注册的批复》 （证监许可〔2021〕1719 号）同意注册，公司首次公 开发行人民币普通股（A 股）股票 25,260.00 万股，每股面值人民币 1.00 元，每 股发行价格为人民币 6.96 元，募集资金总额为人民币 175,809.60 万元，扣除不 含税发行费用人民币 17,431.92 万元，实际募集资金净额为人民币 158,377.68 万 元。普华永道中天会计师事务所（特殊普通合伙）对公司 A 股首次公开发行股票 的资金到位情况进行了审验，并于 2021 年 7 月 5 日出具了普华永道中天验字 (2021)第 0668 号验资报告。公司已对募集资金采取专户存储管理。 中集车辆: 海通证券股份有限公司关于中集车辆 （集团）股份有限公司对A股部分募集资金投资项 目终止并调整投资计划及部分募集资金投资项目延 期的核查意见 海通证券股份有限公司 关于中集车辆（集团）股份 ...

中集车辆: 海通证券股份有限公司关于中集车辆 （集团）股份有限公司对于中集集团财务有限公司 2024年度风险持续评估报告的核查意见 海通证券股份有限公司 关于中集车辆（集团）股份有限公司 对于中集集团财务有限公司 2024 年度风险持续评估报告的核查 根据《深圳证券交易所上市公司自律监管指引第7号——交易与关联交易》 的规定，结合中集集团财务有限公司（以下简称"中集财务公司"）提供的《金融 许可证》及《营业执照》等有关证件资料，中集车辆（集团）股份有限公司审阅 了中集财务公司包括资产负债表、利润表、现金流量表等在内的财务报告、经营 资质、内控制度建设、经营及风险状况，据此，对公司及合并报表范围内的相关 子公司与中集财务公司开展存贷款及其他金融业务的风险进行了持续评估。 一、中集财务公司基本情况 中集财务公司成立于2010年2月9日，是经国家金融监督管理总局批准成立的 非银行金融机构，注册资本为人民币13.26亿元，现有股东单位1家，其中：中国 国际海运集装箱（集团）股份有限公司（以下简称"中集集团"）持股比例为100%。 金融许可证机构代码：L0108H244030001 法定代表人：张力 意见 海通证券股份 ...

Group 1 - The report indicates that Yantai Shichuan Sealing Technology Co., Ltd. has experienced a slowdown in capacity expansion due to significant fluctuations in the commercial vehicle industry, impacting project progress [1][2] - The completion dates for the "Sealing Gasket Technology Upgrade and Expansion Project" and the "Thick Coating Metal Glue Board Technology Upgrade and Expansion Project" have been postponed to December 31, 2025, and December 31, 2026, respectively [2] - The "Thermal Protection Cover Technology Upgrade and Expansion Project" has been terminated, and the remaining raised funds will be retained in a dedicated account for cash management while new investment projects are being considered [2][3] Group 2 - The company has effectively established and executed relevant regulations and internal controls, including those to prevent related party transactions and manage raised funds [1] - The company has conducted one on-site inspection, and the report was submitted in accordance with regulations, with no significant issues identified [1] - The company and its shareholders have fulfilled their commitments, with no unfulfilled commitments reported [2]